The rising prevalence of kidney stone disease is associated with significant costs to healthcare systems worldwide. This is in part due to direct procedural and medical management costs, as well as indirect costs to health systems, patients, and families. A number of manuscripts evaulating the economics of stone disease have been published since the 2008s International Consultation on Stone Disease. These highlight costs associated with stone disease, including acute management, surgical management, and medical management. This work hopes to highlight optimization in care by reducing inefficient treatments and maximizing cost-efficient preventative strategies.
World journal of urology. 2017 Jan 20 [Epub ahead of print]
Noah E Canvasser, Peter Alken, Michael Lipkin, Stephen Y Nakada, Hiren S Sodha, Abdulkadir Tepeler, Yair Lotan
Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9110, USA., Department of Urology, Mannheim University Hospital, Mannheim, Germany., Department of Urology, Duke University, Durham, NC, USA., Department of Urology, University of Wisconsin, Madison, WI, USA., Department of Urology, RG Stone Urology and Laparoscopy Hospital, Andheri, Mumbai, India., Department of Urology, Sen Jorj Austria Hospital, Beyoglu, Istanbul, Turkey., Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9110, USA. .